You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

LOTENSIN HCT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOTENSIN HCT?
  • What are the global sales for LOTENSIN HCT?
  • What is Average Wholesale Price for LOTENSIN HCT?
Summary for LOTENSIN HCT
Drug patent expirations by year for LOTENSIN HCT
Drug Prices for LOTENSIN HCT

See drug prices for LOTENSIN HCT

Recent Clinical Trials for LOTENSIN HCT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Nanjing Children's HospitalPhase 2
University of NebraskaPhase 4
Affiliated Hospital of Yunnan University of Traditional Chinese MedicinePhase 1/Phase 2

See all LOTENSIN HCT clinical trials

US Patents and Regulatory Information for LOTENSIN HCT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Validus Pharms LOTENSIN HCT benazepril hydrochloride; hydrochlorothiazide TABLET;ORAL 020033-001 May 19, 1992 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Validus Pharms LOTENSIN HCT benazepril hydrochloride; hydrochlorothiazide TABLET;ORAL 020033-003 May 19, 1992 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Validus Pharms LOTENSIN HCT benazepril hydrochloride; hydrochlorothiazide TABLET;ORAL 020033-002 May 19, 1992 AB RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Validus Pharms LOTENSIN HCT benazepril hydrochloride; hydrochlorothiazide TABLET;ORAL 020033-004 May 19, 1992 AB RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LOTENSIN HCT

International Patents for LOTENSIN HCT

See the table below for patents covering LOTENSIN HCT around the world.

Country Patent Number Title Estimated Expiration
New Zealand 207091 SUBSTITUTED BENZAZEPINONES AND PHARMACEUTICAL COMPOSITIONS ⤷  Subscribe
Austria 18397 ⤷  Subscribe
Japan H0421665 ⤷  Subscribe
Hong Kong 97592 3-(5-AMINOPENTYL)-AMINO-1-BENZAZEPIN-2-ONE-1-ALCANOIC ACIDS,PROCESS FOR THEIR PREPARATION,THEIR PHARMACEUTICAL PREPARATION AS WELL AS THEIR THERAPEUTIC USE ⤷  Subscribe
Spain 8609262 ⤷  Subscribe
Spain 8504728 ⤷  Subscribe
Israel 70881 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

LOTENSIN HCT Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Lotensin HCT

Introduction

Lotensin HCT, a combination drug consisting of benazepril hydrochloride and hydrochlorothiazide, is widely used for the treatment of hypertension. Understanding its market dynamics and financial trajectory is crucial for pharmaceutical companies, investors, and healthcare professionals.

Mechanism of Action and Clinical Use

Lotensin HCT works by inhibiting angiotensin-converting enzyme (ACE) and acting as a thiazide diuretic, thereby reducing blood pressure. It is indicated for the treatment of hypertension but is not recommended for initial therapy due to potential risks such as agranulocytosis and angioedema, especially in certain patient groups[1].

Market Size and Growth

The global benazepril market, which includes Lotensin HCT, is substantial and growing. As of 2024, the global benazepril market size is estimated at USD 102,514.2 million. This market is projected to expand at a compound annual growth rate (CAGR) of 5.50% from 2024 to 2031, reaching USD 149,125.2 million by 2031[2].

Regional Market Breakdown

  • North America: This region accounts for a significant portion of the market, with sales revenue of USD 57,562.4 million in 2024 and a CAGR of 3.7% from 2024 to 2031. The United States alone contributes USD 32,353.5 million, with a CAGR of 3.5% during the same period[2].
  • Europe: The European market for benazepril is also robust, with sales revenue of USD 30,754.3 million in 2024 and a CAGR of 4% from 2024 to 2031. Countries like the UK, France, and Germany are key contributors to this market[2].
  • Asia Pacific: This region holds around 23% of the global revenue, with a market size of USD 23,578.27 million in 2024 and a CAGR of 7.5% from 2024 to 2031[2].
  • Latin America and Middle East & Africa: These regions contribute smaller but still significant shares, with market sizes of USD 5,125.7 million and USD 2,050.28 million respectively in 2024, and CAGRs of 4.9% and 5.2% from 2024 to 2031[2].

Generic Availability and Competition

Lotensin HCT has generic versions available, which can impact its market dynamics. The FDA has approved several generic formulations of benazepril/hydrochlorothiazide, which are manufactured by various companies including Validus Pharmaceuticals. This competition from generic versions can reduce the market share of the branded drug but also ensures continued availability and affordability for patients[4].

Pricing and Cost Considerations

The pricing of Lotensin HCT and its generic counterparts can vary significantly depending on the region and the specific formulation. Generic versions often offer a more cost-effective alternative, which can be a key factor in market competition. However, the branded version may still maintain a market presence due to brand loyalty and the trust associated with the original manufacturer[5].

Market Drivers

Several factors drive the demand for Lotensin HCT and other benazepril formulations:

  • Increasing Prevalence of Hypertension: The rising global incidence of hypertension is a major driver, as more patients require effective antihypertensive medications.
  • Aging Population: An aging population increases the demand for cardiovascular medications.
  • Advancements in Healthcare: Improved diagnostic techniques and increased awareness about hypertension management contribute to the growing market[2].

Market Restraints

Despite the growth potential, there are several restraints to consider:

  • Side Effects and Risks: Potential side effects such as agranulocytosis, angioedema, and fetal/neonatal morbidity can limit the use of ACE inhibitors like benazepril.
  • Generic Competition: The availability of generic versions can reduce the market share of the branded drug.
  • Regulatory Challenges: Strict regulatory requirements and potential changes in healthcare policies can impact the market[1][2].

Market Trends

  • Increased Focus on Generic and Biosimilar Drugs: The trend towards cost-effective treatments is driving the development and use of generic and biosimilar drugs.
  • Personalized Medicine: There is a growing interest in personalized antihypertensive therapy, which could influence the market dynamics of specific drugs like Lotensin HCT.
  • Digital Health Integration: The integration of digital health technologies in hypertension management could also impact the market by enhancing patient compliance and monitoring[2].

Distribution Channels

The distribution of Lotensin HCT and its generic versions involves various channels:

  • Pharmacies: Retail and online pharmacies are primary distribution points.
  • Hospitals and Clinics: Direct sales to healthcare institutions are also significant.
  • Online Platforms: Reputable online pharmacies play a crucial role, but there is a need to be cautious about fraudulent online sellers[4].

Key Players and Competitors

The market for benazepril and hydrochlorothiazide combination drugs includes several key players:

  • Validus Pharmaceuticals: A major manufacturer of the generic version of Lotensin HCT.
  • Other Generic Manufacturers: Companies like Teva, Mylan, and others that produce generic versions.
  • Branded Drug Manufacturers: Companies that produce branded versions of ACE inhibitors and diuretics[4].

Financial Projections

Given the projected CAGR of 5.50% from 2024 to 2031, the financial trajectory for Lotensin HCT and similar drugs is positive. Here are some key financial projections:

  • Global Revenue: Expected to grow from USD 102,514.2 million in 2024 to USD 149,125.2 million by 2031.
  • Regional Growth: Significant growth is anticipated in regions like Asia Pacific, driven by increasing healthcare expenditure and a growing patient population[2].

Conclusion

The market for Lotensin HCT is driven by the increasing prevalence of hypertension, advancements in healthcare, and the need for effective antihypertensive medications. While generic competition and potential side effects pose challenges, the overall financial trajectory remains positive.

Key Takeaways

  • Growing Market Size: The global benazepril market is expected to grow significantly by 2031.
  • Regional Variations: Different regions have varying growth rates and market sizes.
  • Generic Competition: Generic versions of Lotensin HCT are available and impact the market dynamics.
  • Increasing Prevalence of Hypertension: A major driver of the market.
  • Regulatory and Safety Considerations: Important factors to consider in the use and marketing of Lotensin HCT.

FAQs

Q: What is the primary use of Lotensin HCT? A: Lotensin HCT is primarily used for the treatment of hypertension.

Q: What are the key components of Lotensin HCT? A: Lotensin HCT is a combination of benazepril hydrochloride and hydrochlorothiazide.

Q: Is there a generic version of Lotensin HCT available? A: Yes, generic versions of Lotensin HCT have been approved and are available in the market.

Q: What is the projected growth rate of the global benazepril market? A: The global benazepril market is projected to grow at a CAGR of 5.50% from 2024 to 2031.

Q: What are some of the potential side effects of Lotensin HCT? A: Potential side effects include agranulocytosis, angioedema, and fetal/neonatal morbidity.

Sources

  1. FDA Label for Lotensin HCT: accessdata.fda.gov
  2. Benazepril Market Report 2024: Cognitive Market Research
  3. Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets: FTC
  4. Generic Lotensin HCT Availability: Drugs.com
  5. Lotensin Price Comparison: BFSO Law

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.